0386 Suppl.docx (28.9 kB)
Download fileSupplementary Tables – Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece
dataset
posted on 2022-08-05, 08:45 authored by Figshare Future Science GroupFigshare Future Science Group, Sofia Lampaki, Giannis Mountzios, Vassilis Georgoulias, Aggeliki Rapti, Ioannis Xanthakis, Sofia Baka, Dimitrios Mavroudis, Epaminondas Samantas, Elias Athanasiadis, Flora Zagouri, Andriani Charpidou, Alvertos Somarakis, Christina Papista, Aristeidis Nikolaou, Eleftheria Anastasopoulou, Zoe Paparepa, Konstantinos N Syrigos
Supplementary Table 1: Fist-line Therapy Characteristics, Discontinuation and Switch to 2L.
Supplementary Table 2: T790M mutation testing among patients progressing on or discontinued from 1L EGFR-TKI and Treatment Options.
Supplementary Table 3: Third-, Fourth- and Fifth-line treatments.
